Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term pharmacokinetics. Found 90 abstracts

no pagination
Holt K, Ye M, Nagar S, Korzekwa KR. Prediction of tissue - plasma partition coefficients using microsomal partitioning: Incorporation into physiologically-based pharmacokinetic models and steady state volume of distribution predictions. Drug metabolism and disposition: the biological fate of chemicals. 2019 Oct;47(10):1050-60.   PMCID: PMC6750188
Barone FC, Marcinkiewicz C, Li J, Sternberg M, Lelkes PI, Dikin DA, Bergold PJ, Gerstenhaber JA, Feuerstein G. Pilot study on biocompatibility of fluorescent nanodiamond-(NV)-Z~800 particles in rats: safety, pharmacokinetics, and bio-distribution (part III). International journal of nanomedicine. 2018 Jan;13:5449-68.   PMCID: PMC6149985
Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 2018 Nov;59(11):2595-601.   PMCID: PMC6201295
Lin Q, Wong HL, Tian FR, Huang YD, Xu J, Yang JJ, Chen PP, Fan ZL, Lu CT, Zhao YZ. Enhanced neuroprotection with decellularized brain extracellular matrix containing bFGF after intracerebral transplantation in Parkinson's disease rat model. International journal of pharmaceutics. 2017 Jan 30;517(1-2):383-94.
Nagar S, Korzekwa RC, Korzekwa K. Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation. Molecular pharmaceutics. 2017 Sep 05;14(9):3069-86.   PMCID: PMC5627780
Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 2017 Dec;123(23):4617-30.   PMCID: PMC5856158
Ursu O, Gosline SJ, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS One. 2017 Oct;12(10):e0185650.   PMCID: PMC5638242
Lounsbury N, Mateo G, Jones B, Papaiahgari S, Thimmulappa RK, Teijaro C, Gordon J, Korzekwa K, Ye M, Allaway G, Abou-Gharbia M, Biswal S, Childers W. Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. Bioorganic & medicinal chemistry. 2015 Sep;23(17):5352-9.
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Rapoport N, Gupta R, Kim YS, O'Neill BE. Polymeric micelles and nanoemulsions as tumor-targeted drug carriers: Insight through intravital imaging. J Control Release. 2015 May 28;206:153-60.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015 Aug;26(7):785-92.   PMCID: 4484664
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Doss M. Addition of diagnostic CT scan does not increase the cancer risk in patients undergoing SPECT studies: comment on Brix et al.: radiation risk and protection of patients in clinical SPECT/CT [Comment]. Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S146-7.
Doss M, Kolb HC, Walsh JC, Mocharla VP, Zhu Z, Haka M, Alpaugh RK, Chen DY, Yu JQ. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. Mol Imaging Biol. 2014 Oct;16(5):739-46.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
Jacobs JD, Hopper-Borge EA. Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice. Journal of visualized experiments : JoVE. 2014 Oct 27;92(92):e51917.   PMCID: 4353391
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46.   PMCID: Pmc4209234
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term pharmacokinetics

pharmacokinetics Female Male metabolism drug therapy Middle Aged administration & dosage Aged Neoplasms Adult pathology Drug Dose-Response Relationship adverse effects Drug Administration Schedule Antineoplastic Agents Maximum Tolerated Dose methods Monoclonal Antibodies analogs & derivatives Treatment Outcome drug effects pharmacology antagonists & inhibitors X-Ray Computed Tomography Neoplasm Antigens adverse Deoxycytidine chemistry therapeutic use Oral Administration Cohort Studies Carbonic Anhydrases Mice effects blood Nausea Prognosis Phytogenic Antineoplastic Agents Tissue Distribution 80 and over Aged Intravenous Infusions Inbred C57BL Mice Area Under Curve immunology Antineoplastic Combined Chemotherapy Protocols Tumor Cell Line Paclitaxel IGF Type 1 Receptor chemically induced genetics neurobehavioral function phase I Von Hippel-Lindau Tumor Suppressor Protein Diarrhea Inhibitor of Apoptosis Proteins NF-E2-Related Factor 2 PBPK Antioxidants Folic Acid Tablets Angiogenesis Inhibitors Nerve Growth Factors Fatigue transporter Multimodal Imaging Vascular Endothelial Growth Factor A Atra dexamethasone Hypotension Extracellular Matrix Rats surgery Brain Drug Delivery Systems Optical Imaging modeling and simulation spindle poles Pharmaceutical Solutions Aml DNA Repair secretion Local Neoplasm Recurrence Nanoparticle extravasation Cell Line transplantation in vitro-in vivo prediction (IVIVE) Drug Liberation filanesib kinesin use maximum tolerated dose Oxidative Stress Positron-Emission Tomography Transplantation Half-Life Magnetic Resonance Imaging Pancreatic Neoplasms Taxoids Tumor Biomarkers Animal Disease Models Propionates Metabolic Clearance Rate Animal Models Nude Mice Radiometry Intravital microscopy Follow-Up Studies Biological Models Angiopoietin-2 Pyrroles Randomized Controlled Trials as Topic Keap1 Intra-Arterial Infusions Nanoparticles Heme Oxygenase-1 Drug Carriers Biological Availability therapeutic pharmacodynamics Algorithms Nanodroplets TOR Serine-Threonine Kinases Phase III Clinical Trials as Topic near infrared imaging Polymers Nanoparticle diffusion Cell Survival Sulfonamides Flushing Kidney Neoplasms Perfluorocarbon Neuroimaging Sulfones Drug delivery Neoplasm Drug Resistance Bispecific Antibodies Thiazoles Protein Kinase Inhibitors Insulin-Like Growth Factor II chemical synthesis Syndrome rat modeling Nrf2 Dipeptides Cytokines Basic fibroblast growth factor Genetic Transcription Neuroprotection Microscopy physiologically-based pharmacokinetic modeling
Last updated on Thursday, April 02, 2020